公开(公告)号：US20230279097A1

公开(公告)日：2023-09-07

申请号：US18154116

申请日：2023-01-13

Applicant: Janssen Biotech, Inc.

Inventor： Matteo Cesaroni ,  Matthew Loza ,  Jarrat Jordan ,  Loqmane Seridi

IPC: C07K16/24 ,  G01N33/483 ,  G01N29/44 ,  C12Q1/6883 ,  A61K9/00 ,  A61P37/06 ,  G01N33/564 ,  A61K39/00

CPC classification number: C07K16/244 ,  G01N33/483 ,  G01N29/4418 ,  C07K16/249 ,  C12Q1/6883 ,  A61K9/0019 ,  A61P37/06 ,  G01N33/564 ,  C07K2317/21 ,  A61K2039/505 ,  C12Q2600/158 ,  C12Q2600/106 ,  G01N2333/555 ,  A61K2039/545 ,  C07K2317/76

Abstract: The present invention relates to methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with a safe and effective amount of an anti-IL-12/IL-23p40 antibody or an anti-IL-23 antibody, e.g., informs on what patients to treat with an anti-IL-12/IL-23p40 antibody.

公开(公告)号：US20230265218A1

公开(公告)日：2023-08-24

申请号：US18172987

申请日：2023-02-22

Applicant: Xencor, Inc. ,  Janssen Biotech, Inc.

Inventor： John R. Desjarlais ,  Gregory Moore ,  Michael Hedvat ,  Juan Diaz ,  Veronica Gusti Zeng ,  Matthew Adam Dragovich ,  Joseph Erhardt ,  Theresa McDevitt ,  Fouad Moussa ,  Pankaj Seth ,  Fei Shen ,  Adam Zwolak

IPC: C07K16/46

CPC classification number: C07K16/468 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622

Abstract: Provided herein are novel anti-CD28×anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28×anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3×anti-PSMA antibodies) for the treatment of prostate cancers.

公开(公告)号：US20230243822A1

公开(公告)日：2023-08-03

申请号：US18003185

申请日：2021-06-15

Applicant: JANSSEN BIOTECH, INC.

Inventor： Matthew J. LOZA ,  Keying MA

IPC: G01N33/564 ,  G16B40/00

CPC classification number: G01N33/564 ,  G16B40/00 ,  G01N2800/102 ,  G01N2800/52

Abstract: Biomarkers that are indicative of efficacy of a treatment for rheumatoid arthritis or for the responsiveness to a treatment regimen in a subject being treated for rheumatoid arthritis are described. Also described are probes capable of detecting the biomarkers and related methods and kits for assessing, monitoring, and selecting treatment for rheumatoid arthritis.

公开(公告)号：US20230183360A1

公开(公告)日：2023-06-15

申请号：US18077318

申请日：2022-12-08

Applicant: Janssen Biotech, Inc.

Inventor： Roland Knoblauch

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2863 ,  A61P35/00 ,  C07K2317/565 ,  C07K2317/31

Abstract: The present invention relates to methods of treating colorectal cancer (CRC), such as metastatic colorectal cancer (mCRC), in a subject in need thereof, comprising administering a therapeutically effective amount of an antibody (e.g., a bispecific antibody) to the subject, wherein the antibody specifically binds epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-Met).

公开(公告)号：US20230159633A1

公开(公告)日：2023-05-25

申请号：US17992369

申请日：2022-11-22

Applicant: Janssen Biotech, Inc.

Inventor： Matthew Germinaro ,  Kuan-hsiang Gary Huang ,  Hongyan Zhang

IPC: C07K16/24 ,  A61K45/06 ,  A61K39/395 ,  A61P1/04 ,  A61K31/519 ,  C07K16/28

CPC classification number: C07K16/244 ,  A61K45/06 ,  A61K39/3955 ,  A61P1/04 ,  A61K31/519 ,  C07K16/2887 ,  A61K2039/545

Abstract: A method of treating ulcerative colitis in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial dose and subsequent doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.

公开(公告)号：US20230151083A1

公开(公告)日：2023-05-18

申请号：US17917916

申请日：2021-04-07

Applicant: Janssen Biotech, Inc.

Inventor： Kristof Van Kolen ,  Marc Mercken ,  Rupesh Nanjunda ,  Sanjaya Singh ,  Sherry La Porte ,  Jinquan Luo ,  Pharavee Jaiprasart ,  Sathya Venkataramani ,  Rajkumar Ganesan

IPC: C07K16/18 ,  G01N33/68 ,  A61P25/28 ,  C12N15/63

CPC classification number: C07K16/18 ,  G01N33/6896 ,  A61P25/28 ,  C12N15/63 ,  C07K2317/56

Abstract: Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.

公开(公告)号：US20230149464A1

公开(公告)日：2023-05-18

申请号：US17988910

申请日：2022-11-17

Applicant: Janssen Biotech, Inc.

Inventor： Andrew W. SNOWDEN ,  Ali ZAMANI

IPC: A61K35/17 ,  C12N5/0783 ,  A61P35/00

CPC classification number: A61K35/17 ,  C12N5/0646 ,  A61P35/00 ,  C12N2501/998 ,  C12N2533/20 ,  C12N2501/599 ,  C12N2501/2302 ,  C12N2501/2312 ,  C12N2501/2315 ,  C12N2501/2318 ,  C12N2501/2321

Abstract: The present disclosure is directed to a feeder-cell free methods of producing an expanded natural killer (NK) cell preparation. This method comprises providing a starting preparation of NK cells and treating the starting preparation with a natural killer cell p30-related protein (NKp30) modulating agent alone or with other expansion agents as described herein. The method further involves culturing the treated preparation under conditions effective to expand the starting preparation of NK cells to produce an expanded NK cell preparation. Other aspects of the disclosure related to therapeutic preparations of NK cells produced in accordance with the methods described herein.

公开(公告)号：US20230134748A1

公开(公告)日：2023-05-04

申请号：US17980149

申请日：2022-11-03

Applicant: Janssen Biotech, Inc.

Inventor： Peter Hellemans ,  Ming Qi

IPC: A61K39/395 ,  A61K31/573 ,  C07K16/28 ,  A61K38/47 ,  A61P35/00 ,  A61P7/00

Abstract: This disclosure relates to methods of treating a hematologic malignancy, comprising administering to a subject a therapeutically effective amount of an anti-CD38 antibody and a corticosteroid for a time sufficient to treat the hematologic malignancy, wherein the dosing regimen includes a reduction, elimination, or reduction followed by elimination, of corticosteroid administration to the subject. This disclosure also relates to methods of treating a hematologic malignancy, comprising administering to a subject a therapeutically effective amount of an anti-CD38 antibody and a corticosteroid dose of

公开(公告)号：US20230131727A1

公开(公告)日：2023-04-27

申请号：US17895295

申请日：2022-08-25

Applicant: Janssen Biotech, Inc.

Inventor： Shalom GOLDBERG ,  Donna KLEIN ,  Neeraj KOHLI ,  Theresa Marie MCDEVITT ,  Steven J. ORCUTT

IPC: C07K16/30 ,  A61P35/04 ,  A61K47/68

Abstract: Disclosed herein are antibodies or antigen binding fragments thereof that bind prostate specific membrane antigen (PSMA), polynucleotides, vectors, host cells, radioconjugates, antibody drug conjugates and methods of treating cancer using the same.

公开(公告)号：US20230130600A1

公开(公告)日：2023-04-27

申请号：US17817295

申请日：2022-08-03

Applicant: JANSSEN BIOTECH, INC.

Inventor： Sheri MOORES ,  Smruthi VIJAYARAGHAVAN

IPC: C07K16/28

Abstract: The present invention relates to combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies.